Happenings Archive

What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.

COMPANY:

More Trial Tribulations for Neuralstem
Jan 7, 2014
Without public discussion, Neuralstem (CUR) extended the completion date of its Phase 1 spinal cord injury clinical trial by 2+ years, earning a rare red-flag downgrade from our Monitor. This follows on the heels of a downgrade for its Phase 2 ALS trial in December.
Mixed Signals and a Downgrade for Neuralstem Phase 2 ALS Trial
Dec 6, 2013
NeuralStem's (CUR) CEO claims a six-month follow-up period for patients in its Phase 2 ALS trial, but the trial's record states 24 months. Either way, with the first patient treated in September and recruiting still underway, the trial's anticipated primary completion date (2/2014) is unfeasible. That, plus sites' status change from "active, not recruiting" back to "recruiting," leads our Monitor to downgrade the trial from green- to yellow-flag status.
Neuralstem (CUR) gets FDA nod to initiate Phase 2 trial
Apr 17, 2013
Neuralstem (CUR) announced it received FDA approval to initiate its Phase 2 trial of spinal cord-derived stem cells in ALS. The 15 patient escalating dose trial will test doses up to 16 million cells.
< Previous Page  |  Next Page >